Annovis Bio (ANVS) Cash from Operations (2019 - 2026)
Annovis Bio (ANVS) posted Cash from Operations of 9011624.0 for Q1 2026, down 0.95% sequentially from 8927035.0 in Q4 2025, and down 11.27% YoY from 10155785.0 in Q1 2025.
Annovis Bio (ANVS) Cash from Operations (2019 - 2026) Analysis & Trends
Annovis Bio has reported Cash from Operations for 8 years, with the latest figure at 9011624.0 in Q1 2026.
- Quarterly Cash from Operations fell 11.27% year-over-year to 9011624.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26532163.0 (down 15.55% YoY) and the FY2025 annual result came in at 25619703.0, down 17.01% from the prior year.
- Cash from Operations slipped to 9011624.0 in Q1 2026 per ANVS's latest filing, from 8927035.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 3021789.0 in Q1 2022 and troughed at 11626313.0 in Q1 2023.
- A 5-year average of 6694480.53 and a median of 7032752.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations slumped 284.75% in 2023, then jumped 65.83% in 2024.
- Over 5 years, Cash from Operations stood at 3609398.0 in 2022, then sank by 159.46% to 9364976.0 in 2023, then grew by 11.53% to 8285346.0 in 2024, then declined by 7.74% to 8927035.0 in 2025, then dropped by 0.95% to 9011624.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 9011624.0, 8927035.0, and 3487615.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | -21.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.01 Mn |
| Mar 31, 2026 | -9.01 Mn |
| Dec 31, 2025 | -8.93 Mn |
| Dec 31, 2025 | -8.93 Mn |
| Sep 30, 2025 | -3.49 Mn |
| Sep 30, 2025 | -3.49 Mn |
| Jun 30, 2025 | -5.11 Mn |
| Jun 30, 2025 | -5.11 Mn |
| Mar 31, 2025 | -8.10 Mn |
| Mar 31, 2025 | -8.10 Mn |
| Dec 31, 2024 | -8.29 Mn |
| Dec 31, 2024 | -8.29 Mn |
| Sep 30, 2024 | -3.20 Mn |
| Sep 30, 2024 | -3.20 Mn |
| Jun 30, 2024 | -3.38 Mn |
| Jun 30, 2024 | -3.38 Mn |
| Mar 31, 2024 | -7.03 Mn |
| Mar 31, 2024 | -7.03 Mn |
| Dec 31, 2023 | -9.36 Mn |
| Dec 31, 2023 | -9.36 Mn |